Imaging-guided percutaneous thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms
- 7 Downloads
To evaluate factors that may affect successful ultrasound-guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms (PSA).
Materials and methods
This was an IRB-approved, HIPAA-compliant retrospective study of 326 consecutive subjects (138 males, 188 females; mean age 68 years, range 18–95) who underwent thrombin injection for treatment of femoral PSA; follow-up ultrasound was available in 145 subjects. The number of PSA lobes and dimensions, pre-procedure laboratory values (international normalized ratio [INR], activated partial thromboplastin time [aPTT], platelet count), and concomitant anticoagulation therapy were recorded.
Technical success was achieved in 98.2% (320/326) of subjects. Primary effectiveness (complete thrombosis at 24 h) was achieved in 74.5% (108/145). Twenty-five subjects underwent repeat thrombin injection, successful in 21 subjects, for a total effectiveness rate of 97.0% (129/133). No imaging factor was associated with technique failure, including number of lobes (p = 0.898), largest dimension (p = 0.344), or volume (p = 0.697). No statistically significant difference in pre-procedure INR, aPTT, or platelet count was found between subjects with CT and those with IT (p > 0.138). Anticoagulation therapy was associated with incomplete thrombosis (35.5% [38/107] for CT vs. 63.9% [23/26] for IT; p = 0.002).
Imaging-guided percutaneous thrombin injection has high technical success and effectiveness rates for the treatment of iatrogenic femoral artery PSA. Anticoagulation therapy was the only factor associated with incomplete thrombosis.
KeywordsPseudoaneurysm Percutaneous thrombin injection Ultrasound Anticoagulation
Compliance with ethical standards
Conflict of interest
Wendy Ehieli, Erol Bozdogan, Gemini Janas, Tracy Jaffe, Chad Miller, and Brian Allen have declare that they have no conflict of interest. Mustafa Bashir: Research support, Siemens Healthcare, GE Healthcare, NGM Bio, TaiwanJ Pharma, Madrigal Pharmaceuticals.
This retrospective study was approved by our institutional review board and was compliant with the Health Insurance Portability and Accountability Act. The requirement for written informed consent was waived.
- 2.Etemad-Rezai R, Peck DJ (2003) Ultrasound-guided thrombin injection of femoral artery pseudoaneurysms. Can Assoc Radiol J 54:118-120Google Scholar
- 4.Tisi PV, Callam MJ (2013) Treatment for femoral pseudoaneurysms. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004981.pub4:CD004981 Google Scholar
- 5.Saad NE, Saad WE, Davies MG, Waldman DL, Fultz PJ, Rubens DJ (2005) Pseudoaneurysms and the role of minimally invasive techniques in their management. Radiographics : a review publication of the Radiological Society of North America, Inc 25 Suppl 1:S173-189Google Scholar
- 6.Kontopodis N, Tsetis D, Tavlas E, Dedes A, Ioannou CV (2016) Ultrasound Guided Compression Versus Ultrasound Guided Thrombin Injection for the Treatment of Post-Catheterization Femoral Pseudoaneurysms: Systematic Review and Meta-Analysis of Comparative Studies. European Journal of Vascular and Endovascular Surgery 51:815-823CrossRefGoogle Scholar
- 7.Perler BA (1993) Surgical treatment of femoral pseudoaneurysm following cardiac catheterization. Cardiovasc Surg 1:118-121Google Scholar
- 9.Lumsden AB, Miller JM, Kosinski AS et al (1994) A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. The American surgeon 60:132-137Google Scholar